Psychedelics therapeutics: What we know, what we think, and what we need to research.
David Nutt, Meg J. Spriggs, David Erritzøe
Neuropharmacology September 27, 2022 DOI: 10.1016/j.neuropharm.2022.109257 (opens in new tab)
Study at a glance
AI-extracted from the abstract| Characteristics | Commentary Peer reviewed |
|---|---|
| Topics | Neuroplasticity |
| Keywords | Mental well-being Psychological health Emotional health Behavioral health Brain remodeling Innovative therapies Novel treatments Emerging therapies Advanced treatments Future therapies Breakthrough therapies Paradigm shift New approaches Therapeutic compounds Psychoactive substances Novel compounds Therapeutic substances Mental health tools Psychiatric compounds |
| Citations | 77 |
| Key points | Argues that psychedelic therapy research should be grounded in established facts and current knowledge, and proposes a framework for researchers. |
Abstract
Psychedelic therapy is perhaps the most exciting new development in psychiatry. Not only does it offer a radical new approach to treatment where mainstream approaches have proven ineffective, but the growing evidence for transdiagnostic efficacy is eliciting a re-think of current diagnostic and symptom-specific approaches to psychiatry. This excitement has led to a massive investment in this field with many tens of new pharmaceutical companies being set up to research the effects of known psychedelics and develop new patentable molecules. Whilst this enthusiasm is to be welcomed, it is important that new research is properly grounded in established facts and reflects current knowledge. In this commentary we lay out the knowledge framework that should be taken into account by all innovative researchers in this field.
Citations in the library
Cited by 50
- Psychedelic therapy in the treatment of addiction: the past, present and future Frontiers in Psychiatry June 12, 2023
- Psychedelics: Threshold of a Therapeutic Revolution Neuropharmacology May 27, 2023
- Mini-review: The neurobiology of treating substance use disorders with classical psychedelics Frontiers in Neuroscience April 17, 2023
- Rapid antidepressant-like effect of non-hallucinogenic psychedelic analog lisuride, but not hallucinogenic psychedelic DOI, in lipopolysaccharide-treated mice Pharmacology, Biochemistry, and Behavior December 5, 2022
- Phase 1, placebo-controlled, single ascending dose trial to evaluate the safety, pharmacokinetics and effect on altered states of consciousness of intranasal BPL-003 (5-methoxy-N,N-dimethyltryptamine benzoate) in healthy participants. Journal of Psychopharmacology August 1, 2024
and 45 more in the library
Cites 26
- Trial of Psilocybin versus Escitalopram for Depression New England Journal of Medicine April 14, 2021
- REBUS and the Anarchic Brain: Toward a Unified Model of the Brain Action of Psychedelics Pharmacological Reviews June 20, 2019
- Psychedelics Promote Structural and Functional Neural Plasticity Cell Reports June 1, 2018
- Psilocybin with psychological support for treatment-resistant depression: six-month follow-up. Psychopharmacology November 8, 2017
- MDMA-assisted therapy for severe PTSD: a randomized, double-blind, placebo-controlled phase 3 study. Nature Medicine June 1, 2021
and 21 more in the library